Lionte Catalina, Sorodoc Victorita, Haliga Raluca Ecaterina, Bologa Cristina, Ceasovschih Alexandr, Petris Ovidiu Rusalim, Coman Adorata Elena, Stoica Alexandra, Sirbu Oana, Puha Gabriela, Constantin Mihai, Dumitrescu Gabriela, Gorciac Victoria, Chelariu Andrei-Costin, Catana Andreea Nicoleta, Jaba Elisabeta, Sorodoc Laurentiu
Internal Medicine Department, "Grigore T. Popa" University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.
Second Internal Medicine Clinic, "Sf. Spiridon" Emergency Clinical County Hospital, 700111 Iasi, Romania.
Diagnostics (Basel). 2022 Jun 2;12(6):1373. doi: 10.3390/diagnostics12061373.
Biomarkers were correlated with mortality in critically ill COVID-19 patients. No prediction tools exist for noncritically ill COVID-19 patients. We aimed to compare the independent prognostic value of inflammation and cardiac biomarkers for post-acute COVID-19 patients and the 30-day mortality rate in noncritically ill COVID-19 patients, as well as the relation with the virus variant involved.
This observational cohort study was conducted at an emergency clinical hospital between 1 October 2020 and 31 December 2021. We included consecutive patients with biomarkers determined within 24 h of presentation, followed up at least 30 days postdischarge.
Post-acute COVID-19 was diagnosed in 20.3% of the cases and the all-cause 30-day mortality rate was 35.1% among 978 patients infected with variants of concern. Neutrophil-to-lymphocyte ratio (1.06 [95%CI, 1.01-1.11], = 0.015) and NT-pro BNP were correlated with 30-daymortality, while the monocyte-to-lymphocyte ratio (2.77 [95%CI, 1.10-6.94], = 0.03) and NT-pro BNP (1.68 [95%CI, 1.00-2.84], = 0.05) were correlated with post-acute COVID-19. High-sensitivity to troponin was associated with 30-day mortality (1.55 [95%CI, 1.00-2.42], = 0.05). A Cox proportional-hazards model confirmed that NT-pro BNP was independently associated with mortality. NT-pro BNP remained independently associated with 30-day mortality during follow-up (1.29 [95%CI, 1.07-1.56], = 0.007) after adjustment for confounders.
Inflammation and cardiac biomarkers, determined upon admission and predischarge, in a cohort of hospitalized noncritically ill COVID-19 patients throughout successive pandemic waves, showed a predictive value for post-acute COVID-19 and 30-day mortality.
生物标志物与危重症 COVID-19 患者的死亡率相关。目前尚无针对非危重症 COVID-19 患者的预测工具。我们旨在比较炎症和心脏生物标志物对 COVID-19 康复期患者的独立预后价值以及非危重症 COVID-19 患者的 30 天死亡率，以及与所涉及病毒变体的关系。
这项观察性队列研究于 2020 年 10 月 1 日至 2021 年 12 月 31 日在一家急诊临床医院进行。我们纳入了在就诊后 24 小时内测定生物标志物的连续患者，并在出院后至少随访 30 天。
20.3% 的病例被诊断为 COVID-19 康复期，在 978 例感染相关变体的患者中，全因 30 天死亡率为 35.1%。中性粒细胞与淋巴细胞比值（1.06 [95%CI，1.01 - 1.11]，P = 0.015）和 NT - pro BNP与 30 天死亡率相关，而单核细胞与淋巴细胞比值（2.77 [95%CI，1.10 - 6.94]，P = 0.03）和 NT - pro BNP（1.68 [95%CI，1.00 - 2.84]，P = 0.05）与 COVID-19 康复期相关。高敏肌钙蛋白与 30 天死亡率相关（1.55 [95%CI，1.00 - 2.42]，P = 0.05）。Cox 比例风险模型证实 NT - pro BNP 与死亡率独立相关。在调整混杂因素后，NT - pro BNP 在随访期间仍与 30 天死亡率独立相关（1.29 [95%CI，1.07 - 1.56]，P = 0.007）。
在整个疫情期间连续收治的非危重症 COVID-19 住院患者队列中，入院时和出院前测定的炎症和心脏生物标志物对 COVID-19 康复期和 30 天死亡率具有预测价值。
